Related Experiment Videos
[Study for the experimental chemotherapy and clinical application (author's transl)]
Nihon Sanka Fujinka Gakkai Zasshi
|February 1, 1982
Summary
Experimental chemotherapy using novel drug combinations, including cyclophosphamide (CPM) and vincristine (VCR), shows promise for treating drug-resistant choriocarcinoma. These findings offer new hope for patients with refractory gestational trophoblastic disease.
Area of Science:
- Oncology
- Pharmacology
Background:
- Choriocarcinoma, a gestational trophoblastic neoplasm, often develops drug resistance.
- Standard chemotherapy regimens may be ineffective in advanced or resistant cases.
Observation:
- Experimental chemotherapy in nude mice with drug-resistant choriocarcinoma was studied.
- Initial therapies like methotrexate (MTX) and actinomycin D (ACD) showed variable efficacy.
- Combinations involving cyclophosphamide (CPM) and vincristine (VCR) demonstrated improved outcomes.
Findings:
- In mice, replacing MTX or ACD with CPM, or adding VCR, enhanced treatment effectiveness.
- Two patients with drug-resistant choriocarcinoma showed positive responses to novel combinations.
- One patient achieved complete remission with ACD + CPM after failing multiple prior therapies.
- Another patient experienced HCG titer regression and reduced pulmonary metastasis with ACD + CPM + VCR.
Implications:
- Clinical application of experimental chemotherapy findings is feasible.
- The developed experimental model can guide rational chemotherapy scheduling for drug-resistant choriocarcinoma.
- Novel drug combinations offer potential for improved treatment outcomes in refractory cases.